Targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by biomimetic codelivery
Peer-Reviewed Publication
Updates every hour. Last Updated: 12-Sep-2025 20:11 ET (13-Sep-2025 00:11 GMT/UTC)
https://doi.org/10.1016/j.apsb.2025.04.006
This new article publication from Acta Pharmaceutica Sinica B, discusses targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by biomimetic codelivery.
After 20 years of transformative leadership, Mary Beckerle steps down as CEO and Brad Cairns is named successor to continue advancing cancer research and care across the Mountain West.
If measured from beginning to end, the DNA in our cells is too long to fit into the cell’s nucleus, explaining why it must be constantly folded and packaged. When it is time for cell division, and the genetic information needs to be passed on to the next generation, DNA must be packed particularly tightly, else serious consequences for a cell’s viability might ensue. In a trans-European team effort, researchers from the Max Planck Institute of Molecular Physiology in Dortmund (MPI), the Netherlands Cancer Institute, and the Human Technopole in Milan have now discovered a molecular switch that regulates DNA packing into the typical sausage-shaped chromosomes observed during cell division. The discovery of this central mechanism for cell division has many potential applications in medicine and biotechnology.
MINNEAPOLIS, July 9, 2025 – NMDPSM, a global nonprofit leader in cell therapy, and its collaborative research program, CIBMTR® (Center for International Blood and Marrow Transplant Research®), have released revised donor and cord blood selection guidelines to enhance transplant outcomes for patients. Published in peer-reviewed Journal of Transplantation and Cellular Therapy, the updated guidelines usher in a new era of clinical clarity and standardization around donor choice in hematopoietic cell transplantation (HCT) – enabling transplant centers and researchers access to the latest evidence-based methods for selecting suitable donors for patients who have the 75+ blood cancers and disorders for which transplant is a potential curative therapy.